To investigate the effect of thalidomide adjuvant intensity-modulated chemoradiotherapy on the prognosis of patients with non-small cell lung cancer
ZHANG Lingli
LIU Rongqiang
Abstract：Objective To investigate the effect of adjuvant thalidomide combined with intensively-modulated chemoradiotherapy on prognosis of patients with non-small cell lung cancer(NSCLC).Methods A total of 104 patients with NSCLC in our hospital from February 2020 to March 2021 were randomly divided into control group(n=52)and observation group(n=52).All patients received intensively-modulated chemoradiotherapy,and those in the observation group additionally received adjuvant thalidomide.The clinical efficacy,prognosis,tumor markers(carbohydrate antigen-125[CA125],carcinoembryonic antigen[CEA],cytokeratin 19 fragment[CYFRA21-1]),and angiogenesis indicators(basic fibroblast growth factor[bFGF],vascular endothelial growth factor[VEGF],and vascular endothelial growth factor-C[VEGF-C])before and after treatment were observed between groups.The expression of microRNA-215(miR-215),microRNA-34a(miR-34a),tumor specific growth factor(TSGF),proliferating cell nuclear antigen(PCNA),soluble E-cadherin(sE-cad)and other serum factors were assessed.Results The disease control rate of the observation group was comparable to that of the control group(71.15％vs 55.77％,P＞0.05).After treatment,the 1-month and 3-month serum levels of CA125,CEA and CYFRA21-1 in the observation group were significantly lower than those of control group(P＜0.05).The 1-month and 3-month serum levels of bFGF,VEGF and VEGF-C in the observation group were significantly lower than those of the control group(P＜0.05).The 1-month and 3-month serum levels of miR-34a in the observation group were significantly higher than those of the control group,and the levels of miR-215 were significantly lower(P＜0.05).The 1-month and 3-month serum levels of PCNA,TSGF and sE-Cad in the observation group were significantly lower than those of the control group(P＜0.05).The progression-free survival,overall survival and overall survival rates in the observation group were significantly increased than those of the control group(P＜0.05).Conclusion Adjuvant thalidomide combined with intensity-modulated chemoradiotherapy can reduce the level of tumor markers and prolong the survival of NSCLC patients by inhibiting the expression of angiogenesis indicators,tumor molecules,and micro ribonucleic acid
Keywords：thalidomidenon-small cell lung cancerchemoradiotherapyprognosis
Publication Date：2024-10-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 3061-3065 )